Osaic Holdings’s Taysha Gene Therapies TSHA Stock Holding History

Osaic Holdings’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.2K	Buy	8,838 +6,818	+338%	+$40.3K	﹤0.01%	5342
2026 Q1	$9.03K	Buy	2,020 +1,743	+629%	+$8.11K	﹤0.01%	6360
2025 Q4	$1.53K	Buy	277 +143	+107%	+$694	﹤0.01%	7163
2025 Q3	$426	Hold	134	–	–	﹤0.01%	7570
2025 Q2	$311	Hold	134	–	–	﹤0.01%	7446
2025 Q1	$187	Hold	134	–	–	﹤0.01%	7173
2024 Q4	$233	Hold	134	–	–	﹤0.01%	7145
2024 Q3	$271	Hold	134	–	–	﹤0.01%	7125
2024 Q2	$302	Hold	134	–	–	﹤0.01%	7098
2024 Q1	$387	Hold	134	–	–	﹤0.01%	6868
2023 Q4	$238	Hold	134	–	–	﹤0.01%	7010
2023 Q3	$426	Buy	+134	New	+$250	﹤0.01%	7026
2022 Q2	–	Sell	-241	Closed	-$2K	–	7598
2022 Q1	$2K	Hold	241	–	–	﹤0.01%	6918
2021 Q4	$3K	Hold	241	–	–	﹤0.01%	6912
2021 Q3	$4K	Hold	241	–	–	﹤0.01%	6659
2021 Q2	$5K	Hold	241	–	–	﹤0.01%	6385
2021 Q1	$5K	Buy	+241	New	+$6.53K	﹤0.01%	6180

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Osaic Holdings's TSHA Position: Q2 2026 in Review

Osaic Holdings increased its Taysha Gene Therapies (TSHA) stake by 338% in Q2 2026, buying an estimated $40.3K and bringing the position to 8,838 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5342.

Osaic Holdings first reported a position in TSHA in Q1 2021 and has held it in 17 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Osaic Holdings held 8,838 shares of Taysha Gene Therapies worth $60.2K as of Q2 2026.
Osaic Holdings bought 6,818 Taysha Gene Therapies shares in Q2 2026, an estimated $40.3K.
Taysha Gene Therapies made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #5342 holding.
Osaic Holdings first reported a position in Taysha Gene Therapies in Q1 2021 and has held it in 17 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.